Lisanti Capital Growth LLC Increases Stock Holdings in Glaukos Co. (NYSE:GKOS)

Lisanti Capital Growth LLC raised its holdings in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 39.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 29,790 shares of the medical instruments supplier's stock after acquiring an additional 8,460 shares during the quarter. Lisanti Capital Growth LLC owned approximately 0.05% of Glaukos worth $4,467,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of GKOS. Wellington Management Group LLP raised its stake in Glaukos by 294.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,183,766 shares of the medical instruments supplier's stock worth $284,501,000 after acquiring an additional 1,630,270 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Glaukos by 47.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 641,761 shares of the medical instruments supplier's stock valued at $83,609,000 after acquiring an additional 207,338 shares in the last quarter. Loomis Sayles & Co. L P boosted its stake in shares of Glaukos by 21.6% in the third quarter. Loomis Sayles & Co. L P now owns 673,751 shares of the medical instruments supplier's stock worth $87,776,000 after acquiring an additional 119,527 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Glaukos during the fourth quarter worth about $16,910,000. Finally, State Street Corp raised its stake in Glaukos by 5.3% during the 3rd quarter. State Street Corp now owns 1,954,449 shares of the medical instruments supplier's stock valued at $254,626,000 after purchasing an additional 98,109 shares during the period. Institutional investors own 99.04% of the company's stock.

Remove Ads

Glaukos Trading Up 1.2 %

Shares of NYSE GKOS traded up $1.17 during midday trading on Tuesday, hitting $97.84. The company's stock had a trading volume of 1,004,795 shares, compared to its average volume of 843,384. The business's 50 day moving average is $144.88 and its two-hundred day moving average is $138.66. Glaukos Co. has a 12-month low of $84.08 and a 12-month high of $163.71. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The firm has a market cap of $5.53 billion, a P/E ratio of -34.09 and a beta of 0.99.

Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.02). The company had revenue of $105.50 million during the quarter, compared to the consensus estimate of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. As a group, equities research analysts expect that Glaukos Co. will post -1.08 EPS for the current year.

Insider Transactions at Glaukos

In other Glaukos news, insider Tomas Navratil sold 3,416 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the sale, the insider now owns 72,437 shares of the company's stock, valued at approximately $10,658,380.18. This trade represents a 4.50 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Joseph E. Gilliam sold 3,328 shares of the business's stock in a transaction on Friday, December 20th. The stock was sold at an average price of $149.85, for a total value of $498,700.80. Following the completion of the transaction, the chief operating officer now directly owns 102,169 shares of the company's stock, valued at approximately $15,310,024.65. The trade was a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,744 shares of company stock valued at $2,792,151. 6.40% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

GKOS has been the subject of a number of research analyst reports. Stifel Nicolaus increased their price objective on shares of Glaukos from $153.00 to $175.00 and gave the company a "buy" rating in a report on Tuesday, December 31st. Morgan Stanley downgraded shares of Glaukos from an "equal weight" rating to an "underweight" rating and set a $120.00 price target on the stock. in a report on Monday, December 2nd. Stephens raised shares of Glaukos to a "strong-buy" rating in a report on Monday, December 2nd. Piper Sandler reaffirmed an "overweight" rating and issued a $180.00 target price (up from $140.00) on shares of Glaukos in a report on Monday, January 27th. Finally, Wells Fargo & Company increased their price target on Glaukos from $153.00 to $160.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $163.25.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.